Anti-Mouse CD223 (LAG-3) In Vivo Antibody - Ultra Low Endotoxin
Introducing the Anti-Mouse CD223 (LAG-3) In Vivo Antibody - Ultra Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo research applications. This antibody targets the CD223 (LAG-3) protein, which is crucial in regulating immune responses, making it ideal for studies in immunology and related fields.
With an isotype of rat IgG1, it ensures high purity and ultra-low endotoxin levels (<0.01 EU/μg), perfect for in vivo experiments, flow cytometry, and other immunological assays. Available in various sizes, it is formulated in phosphate-buffered saline for enhanced stability and efficacy. Enhance your research with this reliable and versatile antibody. CD223 (also known as LAG-3) is an immune checkpoint receptor found on the surface of activated T cells, natural killer cells, and regulatory T cells (Tregs). It is involved in the negative regulation of T-cell proliferation, activation, and homeostasis, playing a significant role in maintaining immune tolerance and preventing autoimmunity. This makes it a valuable target in cancer immunotherapy research and autoimmune disease studies.
Product Name:
Anti-Mouse CD223 (LAG-3) In Vivo Antibody - Ultra Low Endotoxin
Product Code:
IVMB0327
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
C9B7W
Protein:
CD223
Product Type:
Monoclonal Antibody
Synonyms:
CD223, LAG3
Isotype:
IgG1
Reactivity:
Mouse
Applications:
B, FA, In Vivo, IP, WB
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Purity:
≥98% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, FA, In Vivo, IP, WB
Reactivity:
Mouse
Host Species:
Rat
Specificity:
Clone C9B7W recognizes and specifically binds to an epitope in the D2 domain of CD223.
Antigen Distribution:
CD223 is expressed on T regulatory cells, activated T cells and NK cells.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥98% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.
Protein:
CD223
Research Area:
Immunology, Inhibitory Molecules
Pathogen Testing:
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Assay Genie's Purified Functional Antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
